{
    "clinical_study": {
        "@rank": "149661", 
        "acronym": "EARTH", 
        "arm_group": [
            {
                "arm_group_label": "Aliskiren", 
                "arm_group_type": "Active Comparator", 
                "description": "Aliskiren group treated with 150-300mg daily aliskiren without diuretics or ACE inhibitors or angiotensin receptor blockers."
            }, 
            {
                "arm_group_label": "Eplerenone", 
                "arm_group_type": "Active Comparator", 
                "description": "Eplerenone group treated with 50-100mg daily eplerenone without diuretics or ACE inhibitors or angiotensin receptor blockers"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to determine which treatment will be more effective\n      to reduce left ventricular mass in hypertensive patients with left ventricular hypertrophy\n      comparing aliskiren and eplerenone."
        }, 
        "brief_title": "Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy", 
        "condition": "Hypertensive Left Ventricular Hypertrophy", 
        "condition_browse": {
            "mesh_term": [
                "Hypertrophy", 
                "Hypertrophy, Left Ventricular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Male or female \u2267 20 years of age Clinical diagnosis of hypertension Patients who are able\n        to provide written informed consent\n\n        Exclusion Criteria:\n\n          1. History of congestive heart failure, myocardial infarction, or coronary\n             revascularization in the recent 6 months.\n\n          2. Planned to taking percutaneous coronary intervention and coronary artery bypass graft\n\n          3. Severe hypertension (\u2267 180/110 mmHg) or secondary hypertension or malignant\n             hypertension.\n\n          4. History of stroke, cerebral hemorrhage, subarachnoid hemorrhage, transient ischemic\n             attack in the recent 6 months\n\n          5. Severe valvular heart disease or atrial fibrillation\n\n          6. Congenital heart disease\n\n          7. Severe heart failure (NYHA functional class \u2163)\n\n          8. Current treatment with aliskiren or eplerenone or diuretics\n\n          9. Taking potassium preparation or potassium-sparing diuretic\n\n         10. Estimated GFR \u2266 30ml/min/1.73m\uff12 at screening or current treatment with hemodialysis\n\n         11. Potassium > 5.0mEq/L at screening\n\n         12. Diabetes mellitus with microalbuminuria or albuminuria\n\n         13. Impairment of liver function (liver failure, liver cirrhosis)\n\n         14. Pregnant woman or possibly pregnant woman\n\n         15. History of malignant tumor include hematological neoplasm\n\n         16. Current treatment with itraconazole, cyclosporin, ritonavir or nelfinavir\n\n         17. Prior treatment with, hypersensitivity to, intolerance of or contra-indication to\n             aliskiren and/or eplerenone\n\n         18. Current participation in another clinical trial\n\n         19. Serious non-cardiovascular disease severely limiting life expectancy\n\n         20. Contra-indication to MRI"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01893788", 
            "org_study_id": "Nagoya University"
        }, 
        "intervention": [
            {
                "arm_group_label": "Aliskiren", 
                "description": "Aliskiren: 150 to 300 mg daily for 48 weeks", 
                "intervention_name": "Aliskiren", 
                "intervention_type": "Drug", 
                "other_name": "Rasilez"
            }, 
            {
                "arm_group_label": "Eplerenone", 
                "description": "50 to 100 mg daily for 48 weeks", 
                "intervention_name": "Eplerenone", 
                "intervention_type": "Drug", 
                "other_name": "Selara"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Angiotensin Receptor Antagonists", 
                "Eplerenone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "hypertension", 
            "left ventricular hypertrophy", 
            "renin angiotensin system", 
            "aldosterone", 
            "aliskiren", 
            "eplerenone", 
            "P3NP"
        ], 
        "lastchanged_date": "July 18, 2013", 
        "location": {
            "contact": {
                "email": "t-nagahiro@med.nagoya-u.ac.jp", 
                "last_name": "Takanori Nagahiro, MD", 
                "phone": "81-52-744-2149"
            }, 
            "contact_backup": {
                "email": "murohara@med.nagoya-u.ac.jp", 
                "last_name": "Toyoaki Murohara, MD, PhD", 
                "phone": "81-52-744-2149"
            }, 
            "facility": {
                "address": {
                    "city": "Nagoya", 
                    "country": "Japan", 
                    "state": "Aichi", 
                    "zip": "466-8550"
                }, 
                "name": "Department of Cardiology, Nagoya University Graduate School of Medicine"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "other_outcome": {
            "description": "BNP, PIIINP etc", 
            "measure": "Biochemical parameters", 
            "safety_issue": "No", 
            "time_frame": "12 month"
        }, 
        "overall_official": {
            "affiliation": "Department of Cardiology, Nagoya University Graduate School of Medicine", 
            "last_name": "Toyoaki Murohara, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To compare the 12 month left ventricular mass or left ventricular mass and index measured by magnetic resonance imaging with baseline.", 
            "measure": "reduction of left ventricular hypertrophy measured by magnetic resonance imaging", 
            "safety_issue": "Yes", 
            "time_frame": "12 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01893788"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Nagoya University", 
            "investigator_full_name": "TOYOAKI MUROHARA", 
            "investigator_title": "Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "total death, composite cardiovascular events, cardiac function eveluated by UCG,reduction of left ventricular hypertrophy measured by UCG", 
            "measure": "Cardiovascular events", 
            "safety_issue": "Yes", 
            "time_frame": "12 month"
        }, 
        "source": "Nagoya University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nagoya University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}